The Economic Times

Wegovy maker Novo Nordisk faces investor pressure to find growth beyond weight-loss drugs

Facing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating diversification into new therapy areas for sustainable growth. With Eli Lilly set to outshine its sales figures this year, analysts suggest a pivot towards developing zenagamtide instead of CagriSema. It is crucial for Novo to navigate patent challenges and competitive threats with a transparent and strategic approach.